Invitrogen™ Tabalumab Chimeric Recombinant Rabbit Monoclonal Antibody (Tabalumab)

Description

Tabalumab neutralises soluble and membrane-bound BAFF, inhibiting BAFF binding to BR3, TACI and BCMA. Eight mice producing serum antibody titers to human BAFF were injected intravenously with 10 μg human BAFF in phosphate buffered saline. The spleen was harvested 3 days later from each mouse and fused with myeloma cells. 20 Hybridomas were tested for specific binding to human BAFF and to make sure they were expressing human immunoglobulin heavy and light chains by enzyme-linked immunosorbent assay (ELISA). The hybridoma producing the antibody that eventually became tabalumab was a human IgG1 isotype. The antibody was then engineered to a human IgG4 isotype for complete neutralization of BAFF without depletion of BAFF-expressing cells.

Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.